Response to the Letter to the Editor: Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA

被引：0
|
作者：
Timothy Fitzgerald
Maryia Zhdanava
Dominic Pilon
Aditi Shah
Patrick Lefebvre
Steven R. Feldman
机构：
[1] Janssen Scientific Affairs,
[2] LLC,undefined
[3] Groupe d’analyse,undefined
[4] Wake Forest University School of Medicine,undefined
来源：
Dermatology and Therapy | 2023年 / 13卷
关键词：
Biologics; Guselkumab; Persistence; Psoriasis; Remission; Treatment discontinuation;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2917 / 2923
页数：6
相关论文
共 50 条
  • [1] Response to the Letter to the Editor: Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA
    Fitzgerald, Timothy
    Zhdanava, Maryia
    Pilon, Dominic
    Shah, Aditi
    Lefebvre, Patrick
    Feldman, Steven R.
    [J]. DERMATOLOGY AND THERAPY, 2023, 13 (11) : 2917 - 2923
  • [2] Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA
    Fitzgerald, Timothy
    Zhdanava, Maryia
    Pilon, Dominic
    Shah, Aditi
    Hilts, Annalise
    Lefebvre, Patrick
    Feldman, Steven R. R.
    [J]. DERMATOLOGY AND THERAPY, 2023, 13 (04) : 1053 - 1068
  • [3] Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA
    Timothy Fitzgerald
    Maryia Zhdanava
    Dominic Pilon
    Aditi Shah
    Annalise Hilts
    Patrick Lefebvre
    Steven R. Feldman
    [J]. Dermatology and Therapy, 2023, 13 : 1053 - 1068
  • [4] Letter to the Editor: Response to Fitzgerald T et al. Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA
    Andrew Blauvelt
    Alyssa Garrelts
    William Malatestinic
    Julie Birt
    Baojin Zhu
    Meghan Feely
    [J]. Dermatology and Therapy, 2023, 13 : 2911 - 2916
  • [5] Response to Fitzgerald T et al. Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA
    Blauvelt, Andrew
    Garrelts, Alyssa
    Malatestinic, William
    Birt, Julie
    Zhu, Baojin
    Feely, Meghan
    [J]. DERMATOLOGY AND THERAPY, 2023, 13 (11) : 2911 - 2916
  • [6] Drug Survival Associated With Effectiveness and Safety of Treatment With Guselkumab, Ixekizumab, Secukinumab, Ustekinumab, and Adalimumab in Patients With Psoriasis
    Yiu, Zenas Z. N.
    Becher, Gabrielle
    Kirby, Brian
    Laws, Philip
    Reynolds, Nick J.
    Smith, Catherine H.
    Warren, Richard B.
    Griffiths, Christopher E. M.
    [J]. JAMA DERMATOLOGY, 2022, 158 (10) : 1131 - 1141
  • [7] Long term psoriasis control with guselkumab versus secukinumab and ixekizumab among bio- experienced patients: analysis of drug persistence in large claims database
    Zhdanava, Maryia
    Fitzgerald, Timothy
    Pilon, Dominic
    Teneralli, Rachel
    Shah, Aditi
    Holiday, Christopher
    Lefebvre, Patrick
    Feldman, Steven
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB188 - AB188
  • [8] Secukinumab: Long-term Safety and Efficacy in Psoriasis
    Hashim, Peter W.
    Lebwohl, Mark G.
    Kircik, Leon H.
    [J]. JOURNAL OF DRUGS IN DERMATOLOGY, 2017, 16 (08) : S115 - S117
  • [9] Drug Survival AssociatedWith Effectiveness and Safety of Treatment With Guselkumab, Ixekizumab,Secukinumab, Ustekinumab, and Adalimumab in Patients With Psoriasis (vol 158, pg 1131, 2022)
    不详
    [J]. JAMA DERMATOLOGY, 2022, 158 (12) : 1461 - 1461
  • [10] Early Response is Associated With Stable Long-Term Response in Psoriasis Patients Receiving Ixekizumab or Ustekinumab
    Augustin, Mathias
    Gallo, Gaia
    See, Kyoungah
    McKean-Matthews, Missy
    Burge, Russel
    Gooderham, Melinda
    Reich, Kristian
    [J]. JOURNAL OF DRUGS IN DERMATOLOGY, 2022, 21 (02) : 14 - 18
12345